| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ... New England Journal of Medicine 372 (4), 311-319, 2015 | 3886 | 2015 |
| An immunogenic personal neoantigen vaccine for patients with melanoma PA Ott, Z Hu, DB Keskin, SA Shukla, J Sun, DJ Bozym, W Zhang, A Luoma, ... Nature 547 (7662), 217-221, 2017 | 2532 | 2017 |
| Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ... Journal of clinical oncology 27 (26), 4247, 2009 | 2402 | 2009 |
| Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK–STAT signaling pathway MA Meraz, JM White, KCF Sheehan, EA Bach, SJ Rodig, AS Dighe, ... Cell 84 (3), 431-442, 1996 | 2061 | 1996 |
| Comprehensive analyses of tumor immunity: implications for cancer immunotherapy B Li, E Severson, JC Pignon, H Zhao, T Li, J Novak, P Jiang, H Shen, ... Genome biology 17, 1-16, 2016 | 1889 | 2016 |
| Adaptive immunity maintains occult cancer in an equilibrium state CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth, ... Nature 450 (7171), 903-907, 2007 | 1759 | 2007 |
| Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ... Nature medicine 24 (5), 679-690, 2018 | 1515 | 2018 |
| MYD88 L265P somatic mutation in Waldenström's macroglobulinemia SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, ... New England Journal of Medicine 367 (9), 826-833, 2012 | 1458 | 2012 |
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ... Nature communications 7 (1), 10501, 2016 | 1414 | 2016 |
| Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and … MR Green, S Monti, SJ Rodig, P Juszczynski, T Currie, E O'Donnell, ... Blood, The Journal of the American Society of Hematology 116 (17), 3268-3277, 2010 | 1385 | 2010 |
| Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade BC Miller, DR Sen, R Al Abosy, K Bi, YV Virkud, MW LaFleur, KB Yates, ... Nature immunology 20 (3), 326-336, 2019 | 1343 | 2019 |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013 | 1292 | 2013 |
| Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses SJ Rodig, MA Meraz, JM White, PA Lampe, JK Riley, CD Arthur, KL King, ... Cell 93 (3), 373-383, 1998 | 1120 | 1998 |
| Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial DB Keskin, AJ Anandappa, J Sun, I Tirosh, ND Mathewson, S Li, ... Nature 565 (7738), 234-239, 2019 | 1096 | 2019 |
| Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ... Journal of clinical oncology 34 (23), 2698, 2016 | 1042 | 2016 |
| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The lancet oncology 17 (9), 1283-1294, 2016 | 994 | 2016 |
| Ibrutinib in previously treated Waldenström’s macroglobulinemia SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ... New England Journal of Medicine 372 (15), 1430-1440, 2015 | 980 | 2015 |
| PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies BJ Chen, B Chapuy, J Ouyang, HH Sun, MGM Roemer, ML Xu, H Yu, ... Clinical cancer research 19 (13), 3462-3473, 2013 | 939 | 2013 |
| Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor JE Butrynski, DR D'Adamo, JL Hornick, P Dal Cin, CR Antonescu, ... New England Journal of Medicine 363 (18), 1727-1733, 2010 | 930 | 2010 |
| Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells KP Koh, A Yabuuchi, S Rao, Y Huang, K Cunniff, J Nardone, A Laiho, ... Cell stem cell 8 (2), 200-213, 2011 | 859 | 2011 |
